UNIRETIC
LOE ApproachingNDAORALTABLET
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UNIRETIC is an oral small-molecule tablet approved in 1997 by UCB Pharma as an NDA. The specific indication and mechanism of action are not disclosed in available data, limiting characterization of its therapeutic scope and patient population.
LOE Approaching
LOE-approaching lifecycle stage signals potential wind-down of brand investment and possible transition to generic support or discontinuation planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
UNIRETIC shows zero linked job openings and LOE-approaching lifecycle status, indicating minimal hiring and career development momentum. Professionals should expect focus on retention, cost management, and potential transition planning rather than growth opportunities.
Brand ManagerField Sales Representative
Worked on UNIRETIC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.